Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APB-G001 is a preclinical-stage mRNA-encoded antibody therapeutic being developed by APITBIO, a South Korean biotechnology company. The drug utilizes APITBIO's proprietary modular antibody mRNA production technology combined with a lipid nanoparticle (LNP) drug delivery system developed in collaboration with Inventage Lab. As an mRNA-encoded antibody, APB-G001 represents an innovative modality that uses messenger RNA to instruct the patient's own cells to produce therapeutic antibodies *in vivo*, rather than administering pre-manufactured protein antibodies. While the specific molecular target and primary indication remain undisclosed, the candidate is currently in the discovery phase and is available for co-research partnerships.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APB-G001.